| Items | Drug Registration information |
|---|---|
| ID | 351 |
| No | 351 |
| Brand Name | LENVACARE 4 |
| Ingredients | LENVATINIB 4 MG |
| Dosage Form | CAPSULE |
| Primary Packaging | BOTTLE |
| Storage | |
| Shelf Life | 3 YEARS |
| Pack Size | BOX OF 30'S |
| Dispensing Category | |
| ATC Classification | |
| Pharmaceutical Class | |
| Indications | AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROIDCARCINIMA, REFRACTORY TO RADIOACTIVE IODINE. AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA WHO HAVE RECEIVED NO PRIOR SYSTEMIC THERAPY |
| Contraindications | |
| Side Effects | |
| Unit Price | |
| EDL | NULL |
| Description | CAPSULE CONTAINS WHITE POWDER |
| Note | |
| License Owner | BOTEN ELEMENTO PHARMA FACTORY |
| Manufacturer | BOTEN ELEMENTO PHARMA FACTORY |
| Country | LAOS |
| Import Registration No | |
| Import Registration Date | |
| Activity | CERTIFICATE RELEASED |
| Applied Date | |
| FDD Registration No | 03 L 0850/21 |
| FDD Registration Date | 20/02/2025 |
| Expiry Date | 19/02/2030 |